+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases



Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases



American Journal of Cardiology 91(12A): 12H-18H, June 19



The immunologic response in atherosclerosis involves not only intrinsic cells of the artery wall, but also circulating leukocytes, lymphocytes, and macrophages. Interaction of various arms of the immune response modulates plaque development and stability, and it is conceivable that immunologic effects of some cardiovascular therapies may contribute to their mechanism of benefit. The preponderance of data has accrued with the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). Statin effects, such as inhibition of T cell activation, tissue factor expression, or reduction of platelet hyperreactivity, may elicit beneficial effects in vitro and in vivo in patients with coronary artery disease. Moreover, aspirin may limit oxidation of lipoproteins and fibrinogen, and it may inhibit cytokine-induced nitric oxide synthase II expression. The hypothesis that selective inhibition of cyclooxygenase-2 (COX-2) may increase risk of myocardial infarction is controversial and may also be of questionable clinical significance. Finally, angiotensin-converting enzyme (ACE) inhibitors not only reduce proinflammatory mediators, such as interleukin-6, but also enhance the concentration of anti-inflammatory cytokines, such as interleukin-10. Because ACE is expressed at the shoulder region of atherosclerotic plaques, and ACE activity is enhanced in unstable plaques, ACE inhibition may also contribute to plaque stability. This article reviews the potential immunomodulatory potencies of aspirin, COX-2 inhibitors, statins, and ACE inhibitors as established pharmacotherapy in patients with coronary artery disease.

(PDF emailed within 0-6 h: $19.90)

Accession: 011308065

Download citation: RISBibTeXText

PMID: 12818730

DOI: 10.1016/s0002-9149(03)00429-6


Related references

Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity. Circulation 109(1): 53-58, 2003

3-Hydroxy-3-Methylglutaryl coenzyme a reductase and angiotensin-converting enzyme inhibitors in cardiac syndrome X Role of superoxide dismutase activity. Circulation 108(17 Supplement): IV-687-IV-688, October 28, 2003

The Possible Therapeutic Actions of Peroxisome Proliferator-Activated Receptor (Ppar) Agonists,Ppar Agonists,3-Hydroxy-3- Methylglutaryl Coenzyme A (Hmg-CoA)Reductase Inhibitors,Angiotensin Converting Enzyme (Ace)Inhibitors and Calcium (Ca)-Antagonists on Vascular Endothelial Cells. Current Drug Target -Cardiovascular & Hematological Disorders 4(1): 35-52, 2004

The possible therapeutic actions of peroxisome proliferator-activated receptor alpha (PPAR alpha) agonists, PPAR gamma agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, angiotensin converting enzyme (ACE) inhibitors and calcium (Ca)-antagonists on vascular endothelial cells. Current Drug Targets. Cardiovascular & Haematological Disorders 4(1): 35-52, 2004

Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in peritoneal dialysis patients. Peritoneal Dialysis International 27(3): 283-287, 2007

Therapeutic Potential of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors for the Treatment of Retinal and Eye Diseases. Cns & Neurological Disorders - Drug Targets 6(4): 282-287, 2007

Therapeutic potential of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the treatment of retinal and eye diseases. Cns and Neurological Disorders Drug Targets 6(4): 282-287, 2007

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Archives of Neurology 67(9): 1062-1067, 2010

Effects of angiotensin II receptor blockers, angiotensin converting enzyme inhibitors, 3-hydroxy-3-methyl glutaryl (HMG) CoA reductase inhibitors, amlodipine and epalrestat on cultured basilar artery smooth muscle cell proliferation. Yakugaku Zasshi 124(3): 159-163, 2004

Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic and Clinical Pharmacology and Toxicology 97(2): 104-108, 2005

Phosphorus containing inhibitors of hydroxy methylglutaryl coenzyme a reductase i design and synthesis of a new class of inhibitors of cholesterol biosynthesis. Abstracts of Papers American Chemical Society 199(1-2): MEDI 67, 1990

Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. Journal of Neuroimmunology 178(1-2): 130-139, 2006

Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis and Rheumatism 62(7): 2073-2085, 2010

Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients. Arzneimittel-Forschung 49(4): 324-329, 1999

Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. American Journal of Cardiology 76(2): 21a-28a, 1995